Merck & Company Inc (MRK)vsCartesian Therapeutics Inc. (RNAC)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
RNAC
Cartesian Therapeutics Inc.
$6.22
-3.86%
HEALTHCARE · Cap: $199.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2324212% more annual revenue ($65.01B vs $2.80M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
RNAC
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+29.3%
Fair Value
$9.07
Current Price
$6.22
$2.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
16.8% revenue growth
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -7029.0% — below average capital efficiency
Earnings declined 7.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : RNAC
The strongest argument for RNAC centers on Revenue Growth. Revenue growth of 16.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : RNAC
The primary concerns for RNAC are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while RNAC is a growth play — different risk/reward profiles.
RNAC carries more volatility with a beta of 0.56 — expect wider price swings.
RNAC is growing revenue faster at 16.8% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 18/100), backed by strong 28.1% margins. RNAC offers better value entry with a 29.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Cartesian Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?